Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...
Amgen down 4% after reporting MariTide weight loss study results
Shares of Amgen (AMGN) are down $11.49, or 4%, to $282.51 in pre-market trading after the company reported data at 52 weeks in a Phase 2 study ...
Evan Seigerman’s Buy Rating on Amgen Driven by Positive MariTide Outlook and Undervaluation
BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...
FierceBiotech6d
Chutes & Ladders—Pfizer replaces retiring CSO with cancer chief
Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...
BioPharma Dive6d
Amgen picks prolific biotech founder Chang as new top scientist
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...